Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Array BioPharma Inc.
Array BioPharma Initiates Clinical Trial in Type 2 Diabetic Patients
April 25th, 2009
Array BioPharma Inc. (Nasdaq: ARRY) announced that it has dosed its first Type 2 diabetic patient in a Phase 1 clinical trial with its novel small molecule glucokinase activator (GKA), ARRY-403. In preclinical studies, ARRY-403 demonstrated effective control of both fasting and non-fasting blood glucose concentrations. The GKA activity of ARRY-403 was shown to be highly dependent on blood glucose concentrations. In the Phase 1 trial, the compound will be evaluated in single- and multiple-dose escalation studies in Type 2 diabetic patients. The study is designed to evaluate safety, tolerability, exposure and blood glucose control. “There is a significant need for new,...
Source: Law & Health Weekly (2009-04-25)
|
